Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Amortization - Intangibles (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Amortization - Intangibles for 11 consecutive years, with $526000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization - Intangibles fell 42.89% to $526000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 10.84% increase, with the full-year FY2025 number at $3.7 million, changed 0.0% from a year prior.
  • Amortization - Intangibles was $526000.0 for Q4 2025 at Aytu Biopharma, up from $444000.0 in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $2.6 million in Q2 2022 to a low of -$226000.0 in Q2 2024.
  • A 5-year average of $1.1 million and a median of $924000.0 in 2023 define the central range for Amortization - Intangibles.
  • Peak YoY movement for Amortization - Intangibles: crashed 118.91% in 2024, then surged 507.52% in 2025.
  • Aytu Biopharma's Amortization - Intangibles stood at $1.1 million in 2021, then rose by 13.02% to $1.2 million in 2022, then fell by 23.37% to $918000.0 in 2023, then grew by 0.33% to $921000.0 in 2024, then plummeted by 42.89% to $526000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Amortization - Intangibles are $526000.0 (Q4 2025), $444000.0 (Q3 2025), and $921000.0 (Q2 2025).